Research ExplorerPublicationsPrognostic and diagnostic role of PSA immunohistochemistry

Prognostic and diagnostic role of PSA immunohistochemistry

Standard

Prognostic and diagnostic role of PSA immunohistochemistry : A tissue microarray study on 21,000 normal and cancerous tissues. / Bonk, Sarah; Kluth, Martina; Hube-Magg, Claudia; Polonski, Adam; Soekeland, Greta; Makropidi-Fraune, Georgia; Möller-Koop, Christina; Witt, Melanie; Luebke, Andreas M; Hinsch, Andrea; Burandt, Eike; Steurer, Stefan; Clauditz, Till S; Schlomm, Thorsten; Perez, Daniel; Graefen, Markus; Heinzer, Hans; Huland, Hartwig; Izbicki, Jakob R; Wilczak, Waldemar; Minner, Sarah; Sauter, Guido; Simon, Ronald.

In: ONCOTARGET, Vol. 10, No. 52, 10.09.2019, p. 5439-5453.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bonk, S, Kluth, M, Hube-Magg, C, Polonski, A, Soekeland, G, Makropidi-Fraune, G, Möller-Koop, C, Witt, M, Luebke, AM, Hinsch, A, Burandt, E, Steurer, S, Clauditz, TS, Schlomm, T, Perez, D, Graefen, M, Heinzer, H, Huland, H, Izbicki, JR, Wilczak, W, Minner, S, Sauter, G & Simon, R 2019, 'Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues', ONCOTARGET, vol. 10, no. 52, pp. 5439-5453. https://doi.org/10.18632/oncotarget.27145

APA

Bonk, S., Kluth, M., Hube-Magg, C., Polonski, A., Soekeland, G., Makropidi-Fraune, G., Möller-Koop, C., Witt, M., Luebke, A. M., Hinsch, A., Burandt, E., Steurer, S., Clauditz, T. S., Schlomm, T., Perez, D., Graefen, M., Heinzer, H., Huland, H., Izbicki, J. R., ... Simon, R. (2019). Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. ONCOTARGET, 10(52), 5439-5453. https://doi.org/10.18632/oncotarget.27145

Vancouver

Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G et al. Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. ONCOTARGET. 2019 Sep 10;10(52):5439-5453. https://doi.org/10.18632/oncotarget.27145

Bibtex

@article{c84bd9d9ba1c4b6891d8f631bab88d05,
title = "Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues",
abstract = "To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9-100% (1:800-1:100) primary tumors, 98.7-99.7% of advanced recurrent cancers, in 84.6-91.4% castration resistant cancers, and in 7.7-18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0-3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0-1 of 21 thyroid gland carcinomas and 0-1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined {"}PSA pattern score{"} was built from staining intensity and pattern. The prognostic impact of the {"}PSA pattern score{"} was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions.",
author = "Sarah Bonk and Martina Kluth and Claudia Hube-Magg and Adam Polonski and Greta Soekeland and Georgia Makropidi-Fraune and Christina M{\"o}ller-Koop and Melanie Witt and Luebke, {Andreas M} and Andrea Hinsch and Eike Burandt and Stefan Steurer and Clauditz, {Till S} and Thorsten Schlomm and Daniel Perez and Markus Graefen and Hans Heinzer and Hartwig Huland and Izbicki, {Jakob R} and Waldemar Wilczak and Sarah Minner and Guido Sauter and Ronald Simon",
year = "2019",
month = sep,
day = "10",
doi = "10.18632/oncotarget.27145",
language = "English",
volume = "10",
pages = "5439--5453",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "52",

}

RIS

TY - JOUR

T1 - Prognostic and diagnostic role of PSA immunohistochemistry

T2 - A tissue microarray study on 21,000 normal and cancerous tissues

AU - Bonk, Sarah

AU - Kluth, Martina

AU - Hube-Magg, Claudia

AU - Polonski, Adam

AU - Soekeland, Greta

AU - Makropidi-Fraune, Georgia

AU - Möller-Koop, Christina

AU - Witt, Melanie

AU - Luebke, Andreas M

AU - Hinsch, Andrea

AU - Burandt, Eike

AU - Steurer, Stefan

AU - Clauditz, Till S

AU - Schlomm, Thorsten

AU - Perez, Daniel

AU - Graefen, Markus

AU - Heinzer, Hans

AU - Huland, Hartwig

AU - Izbicki, Jakob R

AU - Wilczak, Waldemar

AU - Minner, Sarah

AU - Sauter, Guido

AU - Simon, Ronald

PY - 2019/9/10

Y1 - 2019/9/10

N2 - To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9-100% (1:800-1:100) primary tumors, 98.7-99.7% of advanced recurrent cancers, in 84.6-91.4% castration resistant cancers, and in 7.7-18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0-3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0-1 of 21 thyroid gland carcinomas and 0-1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined "PSA pattern score" was built from staining intensity and pattern. The prognostic impact of the "PSA pattern score" was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions.

AB - To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9-100% (1:800-1:100) primary tumors, 98.7-99.7% of advanced recurrent cancers, in 84.6-91.4% castration resistant cancers, and in 7.7-18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0-3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0-1 of 21 thyroid gland carcinomas and 0-1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined "PSA pattern score" was built from staining intensity and pattern. The prognostic impact of the "PSA pattern score" was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions.

U2 - 10.18632/oncotarget.27145

DO - 10.18632/oncotarget.27145

M3 - SCORING: Journal article

C2 - 31534629

VL - 10

SP - 5439

EP - 5453

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 52

ER -